Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $72.94 USD
Change Today +0.09 / 0.12%
Volume 404.2K
As of 1:26 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

l efficiency. Co-registration of angiography and OCT is an advancement in intravascular imaging. Co-registration allows physicians to map the exact location and vessel characteristics of an OCT image with the physician’s view through angiogram. Co-registration allows for improved PCI planning and procedural decision making. Directly measuring pulmonary artery (PA) pressure through a procedure called a right-heart catheterization is the standard-of-care for acute management of worsening HF. The CardioMEMS HF System transmits this same PA hemodynamic data for improved monitoring and management of New York Heart Association (NYHA) Class III HF patients who have been hospitalized for HF in the previous year. The CardioMEMS HF system measures changes in PA pressure, which physicians use to initiate or modify HF treatment prior to symptoms. The CardioMEMS HF System includes three components, including an implantable wireless sensor, a patient electronics system, and a patient database known as the CardioMEMS HF Website. The wireless sensor is designed for permanent implantation into the distal PA through a right heart catheterization procedure. Once implanted, the CardioMEMS PA Sensor provides non-invasive hemodynamic data that is collected in the physician’s office, clinic, hospital or most often, in the patient’s home. The data provided by the HF system includes PA pressure waveform, systolic, diastolic, mean PA pressure and heart rate. This hemodynamic data is transmitted to a Website that serves as the patient database so that PA monitoring information is available at all times through the Internet. The CardioMEMS HF System is an FDA-approved monitor proven to reduce HF hospital admissions and improve quality of life in NYHA class III patients. The company announced European CE Mark approval for the EnligHTN Renal Denervation System and launched EnligHTN outside of the United States in 2012, focused on select countries in Europe and in Australia. The EnligHTN system is a multi-electrode ablation technology that features a non-occlusive basket design that delivers a predictable pattern of four evenly spaced transmural lesions with each catheter placement. This approach allows for continuous blood flow to the kidney during the procedure. The company’s AMPLATZER Vascular Plugs are expandable, cylindrical devices made from nitinol wire that reduce, redirect or eliminate blood flow to unwanted blood vessels. The AMPLATZER Vascular Plug AVP 4 (FDA clearance and European CE Mark approval) has a lower profile and extends the reach of the AMPLATZER vascular plug family to smaller and often more distal blood vessels. The company’s AMPLATZER Vascular Plugs are designed for use in abnormal blood vessels outside the heart, below the neck and above the knee and utilize standard delivery systems commonly used by interventional radiologists and vascular surgeons in these procedures. Structural Heart Products The company’s structural heart valve products facilitate blood flow from the chambers of the heart throughout the entire body. Its structural heart products include transcatheter aortic heart valves (Transcatheter Aortic Valve Replacement), a line of surgical heart valve repair and replacement products, and transcatheter structural heart defect devices. Mechanical Valves: The company’s Regent mechanical heart valve received European CE Mark approval and FDA approval. Tissue Valves: With the acquisition of Biocor Industries, Inc., the company strengthened its position in the tissue heart valve market. The company markets both the Epic and Biocor porcine stented tissue heart valves. The company received European CE Mark approval for its Trifecta tissue heart valve, marking its expansion into the pericardial aortic stented tissue valve market. The Trifecta tissue valve also received FDA approval and the product was launched in Japan. The Trifecta tissue valve has a tri-leaflet stented pericardial design, which offers hemodynamic performance (the optimization of blood flow through the valve) that mimics as closely as possible the flow of a natural, healthy heart valve. The Trifecta valve also features the company

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $72.94 USD +0.09

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.67 USD -0.145
CR Bard Inc $170.67 USD -0.27
Olympus Corp ¥4,230 JPY -5.00
Smith & Nephew PLC 1,074 GBp -10.00
Zimmer Biomet Holdings Inc $109.88 USD +0.59
View Industry Companies
 

Industry Analysis

STJ

Industry Average

Valuation STJ Industry Range
Price/Earnings 21.2x
Price/Sales 3.8x
Price/Book 5.4x
Price/Cash Flow 18.9x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.